DOI: 10.12890/2026_007474
Diagnostically challenging Pro-B ALL followed by emergence of monocytic AML after successful CAR-T treatment
Authors
chensa@tlvmc.gov.il
Keywords
Acute leukemia, monocytic leukemia, myeloid neoplasm, multiparameter flow cytometryAbstract
Introduction: Therapy-related acute myeloid leukemia (t-AML) is a recognized complication of leukemia-directed cytotoxic therapy. However, the emergence of therapy-related monocytic AML shortly after successful CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy for relapsed Pro-B acute lymphoblastic leukemia (B-ALL) raises important questions regarding clonal evolution, lineage plasticity, and treatment-related leukemogenesis.
Case Description: We describe a 73-year-old man diagnosed with Philadelphia chromosome-negative Pro-B ALL with hyperdiploidy/tetraploidy, whose initial presentation posed a diagnostic challenge due to expression of immature and partial myeloid-associated markers, initially suggesting minimally differentiated AML. Repeat immunophenotyping clarified the diagnosis as Pro-B ALL. The patient achieved complete remission with the GMALL Elderly protocol despite severe infectious and treatment-related complications. Following relapse during maintenance therapy, he received salvage treatment with inotuzumab ozogamicin followed by CD19-directed CAR-T therapy, achieving marrow remission. Five months later, he developed secondary monocytic AML with no immunophenotypic evidence of residual B-ALL.
Conclusion: This case underscores the importance of precise immunophenotypic characterization in diagnostically ambiguous acute leukemias and illustrates the complex biologic evolution that may follow sequential chemotherapy and modern immunotherapeutic approaches, including the emergence of secondary myeloid neoplasms after CAR-T therapy.
References
- Bruzzese A, Vigna E, Martino EA, Caserta S, Mendicino F, Alvaro ME, et al. Ph-Negative Acute Lymphoblastic Leukemia in the Older Adults: Biology, Therapeutic Strategies and Unmet Needs. Eur J Haematol. 2026;117(1):24-41. doi: 10.1111/ejh.70169.
- Gökbuget N, Steffen B. How I treat older patients with Ph/BCR-ABL-negative acute lymphoblastic leukemia. Blood. 2025;145(1):53-63. doi: 10.1182/blood.2023023156.
- Kantarjian H, Aldoss I, Jabbour E. Management of Adult Acute Lymphoblastic Leukemia: A Review. JAMA Oncol. 2025;11(7):771-778. doi: 10.1001/jamaoncol.2025.0613.
- Venugopal S, DeZern AE. Therapy-related myelodysplastic syndromes and acute myeloid leukemia. Semin Hematol. 2024;61(6):379-384. doi: 10.1053/j.seminhematol.2024.09.004.
- Rubinstein JD, O’Brien MM. Inotuzumab ozogamicin in B-cell precursor acute lymphoblastic leukemia: efficacy, toxicity, and practical considerations. Front Immunol. 2023;14:1237738. doi: 10.3389/fimmu.2023.1237738.
- Yeoh AE, Tan D, Li CK, Hori H, Tse E, Pui CH; Asian Oncology Summit 2013. Management of adult and paediatric acute lymphoblastic leukaemia in Asia: resource-stratified guidelines from the Asian Oncology Summit 2013. Lancet Oncol. 2013;14(12):e508-23. doi: 10.1016/S1470-2045(13)70452-2.
- Lo Nigro L, Arrabito M, Cannata E, La Rosa M, Iachelli V, Bonaccorso P. Multiple Lineage Switches in a Pediatric Case With a KMT2A::AFF1-Positive Acute Lymphoblastic Leukemia: How Cell Plasticity Induces Immunotherapy Failure. Pediatr Blood Cancer. 2025;72(10):e31950. doi: 10.1002/pbc.31950.
- Weinberg OK. How to think about acute leukemia of ambiguous lineage. Hematology Am Soc Hematol Educ Program. 2024;2024(1):287-292. doi: 10.1182/hematology.2024000554.
- Kaleem Z, White G. Diagnostic criteria for minimally differentiated acute myeloid leukemia (AML-M0). Evaluation and a proposal. Am J Clin Pathol. 2001;115(6):876-84. doi: 10.1309/D2BR-C0V5-LEYD-HA2D.
- Patel SA, Spiegel JY, Dahiya S. Second Primary Cancer After Chimeric Antigen Receptor-T-Cell Therapy: A Review. JAMA Oncol. 2025;11(2):174-181. doi: 10.1001/jamaoncol.2024.5412.
